DNA repair pathways in ovarian cancer: Implications for therapy and resistance
Ovarian cancer (OC) is the gynecological malignancy with the highest mortality, largely due to frequent resistance to conventional therapies. OC is characterized by high rates of genomic instability, often caused by DNA repair defects, and is commonly treated with platinum-based compounds and other...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/412914 |
| Acceso en línea: | http://hdl.handle.net/10261/412914 https://api.elsevier.com/content/abstract/scopus_id/105020891751 |
| Access Level: | acceso abierto |
| Palabra clave: | Base excision repair (BER) DNA damage DNA repair Double-Strand Break (DSB) Homologous Recombination (HR) Mismatch Repair (MMR) Non-Homologous End Joining (NHEJ) Nucleotide Excision Repair (NER) Ovarian cancer PARP inhibitors Single-Strand Break (SSB) Treatment |
| Sumario: | Ovarian cancer (OC) is the gynecological malignancy with the highest mortality, largely due to frequent resistance to conventional therapies. OC is characterized by high rates of genomic instability, often caused by DNA repair defects, and is commonly treated with platinum-based compounds and other genotoxic agents. Indeed, alterations in the DNA damage response (DDR), which are prevalent in many cancers, are particularly relevant in OC. Notably, homologous recombination deficiency is frequently observed, providing a rationale for strategies to enhance treatment efficacy by exploiting DNA repair defects. In this review, we examine the consequences of dysregulation and defects in the major DNA repair pathways in OC, with emphasis on their impact on therapy resistance, patient survival and OC risk. We also discuss current and emerging DDR-targeted therapies and highlight future directions for research aimed at improving clinical outcomes in OC. |
|---|